Exciting Updates from Krystal Biotech: Upcoming Presentations
Krystal Biotech Prepares for Notable Scientific Presentations
Pittsburgh, April 24, 2025 – Krystal Biotech, Inc. (NASDAQ: KRYS) announces its involvement in several prestigious scientific conferences scheduled for May and June. These events will serve as a platform for the Company to present groundbreaking advancements in therapeutic programs targeting the lung, eye, and skin.
The presentations will encompass innovative research findings that are set to impact the future of genetic medicine significantly. Below are the details of the upcoming presentations:
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
During the upcoming ASGCT Annual Meeting, attendees can expect an invited oral presentation focusing on:
- Title: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease
- Presenter: Trevor Parry, PhD
- Date and Time: May 17, 2025, at 8:50 AM CT
2025 American Society of Clinical Oncology (ASCO) Annual Meeting
At the flagship ASCO Annual Meeting, Krystal Biotech will participate through a poster presentation discussing:
- Title: Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study
- Presenter: Wen Wee Ma, MD, Enterprise Vice Chair, Research, Cancer Institute, Cleveland Clinic
- Date and Time: June 2, 2025, from 1:30 PM to 4:30 PM CT
- Poster Session or Category: Developmental Therapeutics – Immunotherapy
- Abstract Number: 2575
- Poster Bd Number: 222
Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
The ARVO Annual Meeting will showcase Krystal Biotech’s advancements through a poster presentation featuring:
- Title: Topical application of the HSV-1-based gene therapy vector KB801 results in sustained nerve growth factor expression in wounded murine corneas
- Presenter: Haley Cartwright, PhD
- Date and Time: May 5, 2025, from 3:00 PM to 4:45 PM MT
- Poster Session or Category: 258 – Preclinical Therapeutics
- Poster Number: B0154
Society for Investigative Dermatology (SID) Annual Meeting
Lastly, the SID Annual Meeting will feature their research on:
- Title: Expansion of an HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases
- Presenter: Bruce Nmezi, PhD
- Date and Time: May 9, 2025, from 4:30 PM to 6:00 PM PT
- Poster Session or Category: Genetic Disease, Gene Regulation, Gene Therapy & Epigenetics
- Poster Number: 0554
These scientific conferences will provide valuable insights into Krystal Biotech's ongoing research initiatives. Following each conference, presentation materials, including slides and posters, will be accessible online for interested stakeholders, showcasing the Company’s commitment to transparency and engagement within the scientific community.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) operates as a fully integrated, commercial-stage biotechnology company dedicated to discovering, developing, and commercializing genetic medicines aimed at addressing diseases with significant unmet medical needs. The Company’s first product, VYJUVEK, is recognized as the first-ever redosable gene therapy approved by the FDA, specifically targeting dystrophic epidermolysis bullosa.
With a robust pipeline of investigational genetic treatments across various fields, including respiratory, oncology, dermatology, ophthalmology, and aesthetics, Krystal Biotech is proud to headquarter its operations in Pittsburgh, Pennsylvania. Interested parties can learn more about Krystal Biotech and its innovative approaches by visiting the official website.
Moreover, the Company actively shares updates and insights through its social media channels on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
Frequently Asked Questions
What is Krystal Biotech known for?
Krystal Biotech is known for its innovative approach to genetic medicine, focusing on the treatment of severe diseases with high unmet medical needs.
What product has Krystal Biotech launched?
Krystal Biotech has launched VYJUVEK, recognized as the first redosable gene therapy approved by the FDA, for the treatment of dystrophic epidermolysis bullosa.
What conferences is Krystal Biotech presenting at?
The Company will present at the ASGCT, ASCO, ARVO, and SID Annual Meetings, showcasing their significant research advancements.
Who will present at the ASGCT Annual Meeting?
Trevor Parry, PhD, will present at the ASGCT Annual Meeting on the use of HSV-1 as a vector for respiratory tissue targeting.
How can stakeholders keep track of Krystal Biotech's updates?
Stakeholders can follow Krystal Biotech on their social media platforms, such as LinkedIn and X, and visit their official website for the latest information.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.